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Abstract The branched-chain amino acid aminotransferase,
Bcat1/Eca39, catalyzes the first step of branched-chain amino
acid catabolism. Bcat1/Eca39 was originally isolated from a
c-myc-induced tumor and was proven to be a direct target for
c-Myc regulation. The gene is highly conserved in evolution and
disruption of its yeast homolog affects cell growth. To assess the
role of Bcat1/Eca39 in mammalian cells, we overexpressed
Bcat1/Eca39 in murine cells and studied effects on cell growth.
Overexpression of Bcat1/Eca39 had no apparent effect on the
proliferation of cells grown with high serum concentrations, but
under serum deprivation conditions, led to a decrease in cell
viability. Cell death under these conditions displayed apoptotic
features. The branched-chain keto acid, K-ketoisocaproate, a
metabolite of leucine catabolism produced by BCAT1/ECA39,
was previously found to inhibit cell growth. We show that
K-ketoisocaproate can induce rapid apoptotic cell death. This
observation suggests that the growth inhibitory effect of BCAT1/
ECA39 and its apoptosis promoting effect may be mediated by
the levels of the products of BCAT1/ECA39 activity, namely,
branched-chain keto acids.
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1. Introduction
Catabolism of branched-chain amino acids (BCAA) is a
major pathway in the metabolism of essential amino acids.
This pathway allows the utilization of BCAA for energy pur-
poses and as a source of various direct and indirect metabo-
lites such as glutamate [1]. The signi¢cance of this pathway is
best demonstrated in maple syrup urine disease (MSUD),
where as a result of mutations in another enzyme in the path-
way, BCAA and branched-chain keto acids (BCKA) accumu-
late, and the patients su¡er from mental and physical retar-
dation sometimes leading to coma and death [2]. Branched-
chain amino acid aminotransferases (BCATs) are the enzymes
regulating the ¢rst step in degradation of BCAA, and the
genes coding for these enzymes were recently isolated [3,4].
Bcat1/Eca39 codes for the cytosolic branched-chain amino
acid aminotransferase and is expressed in a wide range of
mammalian embryonic tissues [5^7], while in adult life it is
mainly found in the brain and kidney [8,9]. The other BCAT
isoenzyme (BCAT2/ECA40) is mitochondrial and is consid-
ered to be a housekeeping protein found in all tissues [5,8]
and not sensitive to cell proliferation state [10].
The Bcat1/Eca39 gene is directly regulated by c-Myc. It was
isolated by a subtraction/co-expression strategy utilizing c-
Myc-induced tumors from transgenic mice [7]. Eca39 harbors
a functional c-Myc binding motif and has been shown to be a
direct target for c-Myc activation in both mouse and man
[7,9,11]. c-myc is a major regulator of cell growth, di¡erentia-
tion and oncogenesis (for reviews see references [12^15]). Cell
culture studies have shown that overexpression of c-myc can
induce cells to enter the cell division cycle and proliferate
[16,17]. Yet, overexpression of c-myc in serum deprived cul-
tured cells can also induce apoptosis [18,19]. The myc family
of proto-oncogenes codes for transcription factors [15,20,21]
which together with another nuclear protein, Max, bind a
speci¢c DNA sequence and activate transcription [22,23].
The pathways by which c-Myc induces cellular processes
such as proliferation, di¡erentiation or apoptosis, are still ob-
scure and only a small number of target genes, directly regu-
lated by c-Myc, have been identi¢ed so far [15,24].
To study the function of Eca39, its possible e¡ects on cell
proliferation and its possible involvement in Myc-induced
processes, we have recently characterized several homologs
of ECA39 from vertebrates and invertebrates [4,25,26]. We
disrupted the Saccharomyces cerevisiae homolog of Eca39
and found that yeast cells lacking ECA39 grew faster due to
shortening of the G1 stage of the cell division cycle [26]. These
observations suggest that ECA39 may have an anti-prolifer-
ative e¡ect on growth. In the present work, we study the
involvement of Bcat1/Eca39 in proliferation and apoptosis
in mammalian cells.
2. Materials and methods
2.1. plasmids and cells
pPGK-ECA39, an expression vector in which Bcat1/Eca39 cDNA is
under the control of the phospho-glycerate kinase-1 (PGK-1) pro-
moter was constructed by inserting a BbrpI-XhoI 1292 bp fragment
from the murine Eca39 cDNA into the SmaI-XhoI sites of pCA1038
[27]. The PGK-neo plasmid [27] was used as a selective marker.
NIH3T3 cells were grown in Dulbecco’s modi¢ed Eagle’s medium
(DMEM) supplemented with 10% fetal calf serum (Biological Indus-
tries, Israel), 50 units/ml of penicillin G, 50 mg/ml of streptomycin
and 4 mM L-glutamine. DNA was transfected into NIH3T3 cells by
electroporation (960 WF, 250 V, 200 6, BioRad Gene Pulser) [28].
Transfectants were selected with 0.4 mg/ml G-418.
2.2. RNA isolation and Northern blot analysis
Total RNA was extracted using guanidine thiocyanate and centri-
fuged through a CsCl cushion by the method of Chirgwin et al. [29].
Northern blot analysis was performed as described [30]. DNA probes
were labeled with a random priming kit (Boehringer Mannheim) using
[Q-32P]dCTP (3000 Ci/mM; ICN).
2.3. Expression of recombinant proteins and preparation of polyclonal
antibodies against BCAT1/ECA39
Bcat1/Eca39 was expressed in bacteria using the QIAexpressionist
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system (Qiagen). A PstI-XhoI 1.2 kb fragment of Bcat1/Eca39 cDNA
was cloned into the PstI-HindIII sites of pQE32 producing an induc-
ible expression vector coding for a His-tagged BCAT1/ECA39 pro-
tein. Expression was induced with 0.2 mg/ml IPTG for 3 h. The ex-
pressed protein appeared in inclusion bodies and was puri¢ed using
His-Bind beads obtained from Novagen according to supplied proto-
col. The puri¢ed recombinant protein was used to produce polyclonal
antibodies in rabbits according to standard procedures [31].
2.4. Cell extract preparation, BCAT activity assay and Western blot
analysis
Cell extracts were prepared by homogenization as described [32].
Western blot analysis was performed as described by Towbin et al.
[33]. Thirty Wg protein from each extract were separated by SDS-
PAGE in a 10% polyacrylamide gel. Polyclonal anti-BCAT1/ECA39
was used at 1/10 000 dilution as the primary antibody, and goat anti-
rabbit IgG (whole molecule) alkaline phosphatase-conjugated (Sigma)
was used as the secondary antibody. BCAT activity was assayed by
measuring branched-chain keto acids produced using a colorimetric
assay as previously described [4], except potassium phosphate pH 7.8
was used as bu¡er.
2.5. Proliferation rate, TUNEL and FACS analyses
Cell proliferation rate was determined using a WST-1 kit (Boehr-
inger Mannheim), a colorimetric assay for mitochondrial dehydro-
genases in viable cells. 3000 cells/well were plated in a 96-well plate
with 10% fetal calf serum (FCS). Cells were allowed to grow for 16 h
before cell viability was examined. Each point was measured in trip-
licate. For starvation, cells were initially plated and allowed to grow
for 16 h in 10% FCS, before transferring them to fresh starvation
medium with 0.2% FCS.
FACS analysis of cellular DNA content for estimation of cell cycle
stage distribution, was performed as described [34]. Brie£y, cells were
¢xed in ethanol, washed with PBS, treated with phosphate-citrate and
Rnase A, and stained with propidium iodide.
TUNEL assay for detection of apoptotic cells using biotin-16-
dUTP and ExtraAvidin-TRITC was performed as described [35]. De-
tection of TUNEL-stained nuclei by alkaline phosphatase was per-
formed using a standard kit from Boehringer Mannheim.
3. Results
3.1. Overexpression of Bcat1/Eca39 in NIH3T3 cells
To obtain cell lines overexpressing Bcat1/Eca39, NIH3T3
cells were stably transfected with an expression vector con-
taining the Bcat1/Eca39 cDNA under the control of the
PGK1 promoter. The PGK-neo vector was co-transfected to
permit selection for G-418 resistant transfectants. Cells trans-
fected with the PGK-neo vector alone were used as controls.
Several resistant clones were isolated and expression of PGK-
Eca39 was con¢rmed in eight of them by Northern blot anal-
ysis with a Bcat1/Eca39 speci¢c probe (Fig. 1A). Since the
expression vector lacks 0.9 kb of the 3P untranslated region
of the Bcat1/Eca39 gene, the exogenous transcript appears
smaller than the endogenous transcript (1.5 kb vs. 2.4 kb).
Expression of the endogenous Bcat1/Eca39 is dependent on
the proliferative state of the cells ; it is high in dividing cells
and decreases in arrested cells (Fig. 1B and [10]). Expression
of the exogenous PGK-Eca39 gene does not seem to be de-
pendent on cell proliferation. It is constitutively expressed in
dividing cells and in cells arrested either by serum starvation
or by allowing cells to grow to con£uence (Fig. 1B).
Overexpression of BCAT1/ECA39 at the protein level was
con¢rmed by Western blot analysis using an antibody devel-
oped against a recombinant BCAT1/ECA39 protein, ex-
pressed in bacteria (see Section 2). A band of about 40 kDa
corresponding to the BCAT1/ECA39 protein was detected
(Fig. 1C). An additional smaller faint band was also labeled,
but this band was also evident when using the pre-immune
serum, and thus could serve as a reference to compare the
amounts of protein loaded on the gel (Fig. 1C).
Transamination of each of the three branched-chain amino
Fig. 1. Overexpression of Bcat1/Eca39 in NIH3T3 cells. A: NIH3T3 cells were transfected with pPGK-ECA39 (ECA39) and PGK-neo, or only
with the selection marker PGK-neo (Neo). Several stable clones were isolated from each experiment. Total RNA was prepared from the various
clones, blotted and hybridized with a probe for Bcat1/Eca39. An endogenous transcript of 2.4 kb was recognized in all cells and a new tran-
script of about 1.5 kb was seen in most of the cell lines transfected with pPGK-ECA39. B: Expression of Bcat1/Eca39 in di¡erent proliferation
states: dividing cells (D), con£uent cells (C) and serum-deprived cells (0.1% FCS) (S). Note that the endogenous gene is repressed in non-prolif-
erative conditions, while the exogenous gene with the PGK1 promoter is not sensitive to the proliferative state. C: Western blot analysis of
BCAT1/ECA39 expression. Thirty Wg of protein from cell extracts from Bcat1/Eca39 overexpressing cells (ECA39) and control cells (Neo) were
separated by SDS-PAGE. Expression of Bcat1/Eca39 was determined using an antibody raised against a recombinant BCAT1/ECA39 protein
(see Section 2). D: BCAT activity in cells overexpressing Bcat1/Eca39 (ECA39) and in control cells (Neo) grown for 24 h in 0.2% FCS. Activ-
ity was measured using leucine, isoleucine or valine as substrate. Results are given in units relative to the control activity for each substrate.
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acids (leucine, valine and isoleucine) was examined in two
clones. A 2^5-fold increase in BCAT activity was observed
in extracts from cells transfected with the Bcat1/Eca39 expres-
sion vector compared to control cells (Fig. 1D).
3.2. Proliferation rate of Bcat1/Eca39 overexpressing cells
To study the involvement of BCAT1/ECA39 in cell prolif-
eration, we determined the growth rate of cells overexpressing
Bcat1/Eca39 in high or low serum conditions. In medium
containing 10% FCS, no signi¢cant di¡erence in growth rate
between overexpressing and control cells was observed and no
foci were detected when cells were allowed to grow to con£u-
ency (data not shown). However, in 0.2% FCS, the growth
rate of Bcat1/Eca39 overexpressing cells was signi¢cantly low-
er than that of the control cells (Fig. 2), indicating that Bcat1/
Eca39 overexpressing cells are more sensitive to serum starva-
tion conditions. Some variations were observed between
clones but average results from four di¡erent clones showed
a signi¢cant (P6 0.005) decrease in cell viability of Bcat1/
Eca39 overexpressing cells and increased cell death after
2 days in low serum (Fig. 2).
3.3. Cell death in Bcat1/Eca39 overexpressing cells
Overexpression of c-myc, the regulator of Bcat1/Eca39, in
¢broblasts induces apoptosis during serum starvation [18]. To
determine whether the excessive cell death of serum-starved
Bcat1/Eca39 overexpressing cells was due to apoptosis we
searched for apoptotic features in these cells compared to
control cells. Cells were grown for 2 days in 0.2% FCS and
cellular DNA content was determined by FACS analysis. The
population of cells with sub-G1 DNA content, characteristic
of apoptotic cells, was signi¢cantly larger in serum-starved
Bcat1/Eca39 overexpressing cells than that found in control
cells (Fig. 3A). The fraction of sub-G1 cells varied between
overexpressing clones (9^25%) with an average of 16 þ 4.6%
(mean þ S.E.), and was signi¢cantly higher (P6 0.05) than in
control cells (6 þ 0.3%).
To demonstrate DNA fragmentation in intact cells we per-
formed a TUNEL assay in which terminal transferase is used
to label free DNA ends. The assay detected excessive DNA
fragmentation in nuclei of Bcat1/Eca39 overexpressing cells
(Fig. 3B). By counting cells in several ¢elds we estimated
that the nuclei of about 32% of Bcat1/Eca39 expressing cells
were positively stained by the TUNEL assay compared to
only 3% of control cells (Fig. 3B). Since dying cells tend to
disintegrate, some of them are lost during preparation of cells
for FACS analysis. This, together with the better sensitivity of
TUNEL compared to FACS, can explain the variation in the
fraction of apoptotic cells identi¢ed by the two methods. In
addition to DNA fragmentation, DAPI staining of serum-
starved cells overexpressing Bcat1/Eca39 demonstrated con-
densed chromatin in many nuclei (Fig. 3B), another frequent
feature of apoptosis.
3.4. E¡ect of K-ketoisocaproate (KIC) on NIH3T3 cells
Eca39 codes for the metabolic enzyme branched-chain ami-
no acid aminotransferase (BCAT, EC 2.6.1.42) [3,4]. This en-
zyme catalyzes the ¢rst step of branched-chain amino acid
(BCAA) catabolism, transferring the amine group from the
BCAA to K-ketoglutarate, producing glutamate and leaving
the BCAA in their keto form.
The e¡ect of Bcat1/Eca39 overexpression on cell viability
may be independent of its de¢ned enzymatic activity. Alter-
natively, overexpression of BCAT may promote cell death
through changes in the levels of metabolites involved in the
Fig. 2. Viability of cells overexpressing Bcat1/Eca39 under serum
starvation conditions. Growth rate of cells grown in DMEM with
low serum (0.2% FCS) was followed for 3 days and estimated by
WST-1 assay (described in Section 2). Each point represents meas-
urements from four Bcat1/Eca39 expressing cell lines (ECA39) or
three control cell lines (Neo) done in triplicate (mean þ S.E.).
Fig. 3. Apoptotic features in serum-starved cells overexpressing
Bcat1/Eca39. A: FACS analysis of Bcat1/Eca39 overexpressing
(ECA39) and control (Neo) cell lines after 2 days in DMEM with
0.2% FCS. The plots represent one clone of each type. To estimate
the G1 population and apoptotic (sub-G1) population data from
three clones of each type were analyzed using Mod¢t LT software.
In Bcat1/Eca39 overexpressing cells about 16 þ 4.6% (mean þ S.E.)
of the cells appeared in the sub-G1 fraction compared to 6 þ 0.3%
in control cells (P6 0.05). B: TUNEL assay for detection of apop-
totic cells. Bcat1/Eca39 expressing (ECA39) and control (Neo) cells
were grown for 2 days in DMEM with 0.2% FCS, ¢xed and ana-
lyzed by TUNEL staining using biotin-16-dUTP and ExtraAvidin-
TRITC. About 32% of nuclei were positively stained in Bcat1/Eca39
expressing cells, compared to 3% in the control. DAPI staining was
used to detect nuclei and observe their morphology.
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transamination reaction. These metabolites include the
branched-chain amino acids (leucine, isoleucine and valine),
the branched-chain keto acids (K-ketoisocaproate, K-keto-L-
methylvalerate and K-ketoisovalerate), glutamate and K-keto-
glutarate. The e¡ects of BCAA and BCKA on cells and tis-
sues were analyzed in studies relating to the genetic disease
known as maple syrup urine disease (MSUD), in which a
defect in the second step of BCAA catabolism (dehydrogen-
ation of BCKA) results in accumulation of BCAA and BCKA
[2]. In these studies K-ketoisocaproate (KIC) was reported to
inhibit cell proliferation and prolong the G1 stage of the cell
division cycle [36]. We therefore studied the e¡ects of BCAA
and BCKA on proliferation of NIH3T3 cells and asked
whether high levels of KIC can simulate Bcat1/Eca39 over-
expression and induce cell death even when cells are grown in
high serum. As shown in Fig. 4, addition of KIC to the me-
dium induced rapid cell death. Within 2^4 h from the addition
of KIC, cells shrank, detached from the plate, assumed a
round morphology and appeared more refractile.
Proliferation rates depended on the concentrations of KIC
in the medium: concentrations of 80 mg% KIC inhibited cell
proliferation and concentrations of 120 mg% were su⁄cient to
induce almost complete cell death within 30 h (Fig. 5). This
e¡ect was speci¢c to KIC and was not observed with its re-
lated BCAA, leucine (Fig. 5). The highest concentration used
in these experiments was 200 mg% (13 mM), because such
concentrations were reported for BCAA and BCKA in blood
tests of untreated MSUD patients [2,36], while in blood tests
of healthy people, BCKAs were detected only in WM levels [2].
Signi¢cant cell death was observed as early as 2 h after
addition of KIC to NIH3T3 cells. Such a rapid response sug-
gests an active mechanism of cell death. To determine if KIC
induces apoptosis in these cells we used FACS analysis and
TUNEL staining. A summary of four FACS analyses of KIC
treated cells is presented in Fig. 6A. A large sub-G1 popula-
tion, characteristic of apoptotic cells, was found in KIC
treated cultures. As shown in Fig. 6B, the TUNEL assay
also detected apoptotic cells in KIC treated samples but not
in untreated control cells. A large fraction of the treated cells
(about 25%) was positively stained after incubation of only 4 h
with KIC. The use of alkaline phosphatase for identifying
apoptotic cells clearly shows that cells are intact when DNA
fragmentation is already evident (Fig. 6B). This is a basic
feature of apoptosis in contrast to other mechanisms of cell
death. Taken together, the results show that KIC induces
apoptosis in NIH3T3 cells when added in physiological con-
centrations.
4. Discussion
c-Myc has diverse e¡ects on cellular processes. It can pro-
mote cell proliferation as well as cell death, it can induce
malignant transformation and is essential for embryonic de-
velopment. Though the molecular mechanisms whereby these
processes are exerted are relatively unknown, c-Myc probably
promotes the various processes through the regulation of its
target genes and in coordination with other factors present in
cells. We set out to assess the role of Bcat1/Eca39, a target for
c-Myc regulation, in cellular growth. Previous studies have
indicated that disruption of the gene in yeast cells results in
an accelerated growth rate [26], suggesting an anti-prolifera-
tive role for Bcat1/Eca39. In the current work we demonstrate
a similar role for Bcat1/Eca39 in mammalian cells as well :
overexpression of Bcat1/Eca39 inhibits cell growth and re-
duces cell viability (Fig. 2).
Serum deprivation directs cells into growth arrest but in
most cases is not su⁄cient to induce programmed cell death.
Fig. 4. Cells grown for 4 h with or without KIC (200 mg%). In the
presence of KIC many cells are detached from the surface and ap-
pear more refractile.
Fig. 5. E¡ect of KIC on growth of NIH3T3 cells. Growth of cells
in 10% FCS with increasing concentrations of KIC (upper panel) or
leucine (lower panel). Cell growth was followed for 48 h and esti-
mated by a WST-1 assay. Each point represents three measurements
(mean þ S.E.).
FEBS 22500 25-8-99
A. Eden, N. Benvenisty/FEBS Letters 457 (1999) 255^261258
However, expression of c-myc in serum deprived cells can
induce apoptosis [18]. Since Bcat1/Eca39 was identi¢ed as a
c-Myc target we asked whether the death of cells overexpress-
ing Bcat1/Eca39 is also the result of apoptosis. We therefore
searched for apoptotic features in these cells. No single crite-
rion exists for characterization of apoptotic cell death and not
all apoptotic features are manifested in all cell types [34,37]. A
common apoptotic feature is chromatin condensation fol-
lowed by DNA fragmentation [37]. The results presented
clearly show DNA fragmentation in intact cells detected by
FACS and TUNEL analyses. DNA appeared degraded also
when separated in agarose gel, though not in a ladder pattern
(results not shown). Cell shrinkage and chromatin condensa-
tion were also observed (Fig. 3B), supporting the hypothesis
of an apoptotic mechanism of cell death.
The anti-proliferative e¡ect is evident in low serum condi-
tions. This may indicate that the pathway is dependent also
on environmental signals supplied by the serum. Another ex-
planation is that because the endogenous Bcat1/Eca39 is re-
pressed only at low serum concentrations, the increase in ex-
pression due to the presence of the exogenous gene is not
signi¢cant in high serum conditions and has no biological
e¡ect. In such a situation, disruption of the gene will decrease
ECA39 activity in high serum conditions and reveal its e¡ect
on proliferation rate as observed in yeast cells [26].
Considering the recent ¢nding that ECA39 is a branched-
chain amino acid aminotransferase (BCAT) [4], it is unlikely
that BCAT1/ECA39 directly regulates the cell cycle. It seems
more probable that changes in the levels of metabolites in-
volved in the transamination reaction or changes in the gen-
eral metabolic state of the cell, mediate an indirect e¡ect on
cell division cycle progression. Two of the metabolites pro-
duced by BCAT have been previously proposed to a¡ect cell
growth: One is glutamate, a well characterized inducer of
neuronal cell death via a speci¢c receptor on the cell mem-
brane [38], and the other is KIC which was shown to inhibit
cell proliferation [36]. While glutamate levels in the cell are
a¡ected by several metabolic pathways, KIC levels are regu-
lated directly by BCAT1/ECA39. Our results show that KIC
can e⁄ciently inhibit cell proliferation and can induce apop-
Fig. 6. A: NIH3T3 cells were grown with or without KIC (200 mg%) for 12 h. Cellular DNA content was determined using FACS analysis.
The proportions of sub-G1 (apoptotic), G1, S and G2/M cells are shown. Each column represents data from four independent experiments
(mean þ S.E.). B: TUNEL assay of cells grown with or without KIC (200 mg%) for 4 h. TUNEL was performed using TRITC or alkaline
phosphatase for detection of labeled DNA. About 25% of cells were positively stained compared to less than 0.5% in the control. DAPI stain-
ing was used to detect nuclei and observe their morphology.
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tosis, when added at concentrations seen in MSUD patients.
The apoptotic characteristics displayed by serum-starved cells
overexpressing Bcat1/Eca39 and by cells exposed to KIC are
similar. The di¡erences in the proportions of dead cells result
from the di¡erent natures of the two systems: Unlike the
death of Bcat1/Eca39 overexpressing cells which is a more
stochastic phenomenon, cells treated with KIC are exposed
simultaneously and therefore respond more rapidly and uni-
formly. The anti-proliferative e¡ect and the drastic apoptotic
e¡ect of high KIC levels on NIH3T3 cells o¡er a mechanistic
explanation for the results obtained from overexpressing
Bcat1/Eca39 in mammalian cells. We propose that the e¡ects
of BCAT1/ECA39 on cell growth are mediated by KIC levels,
which are regulated by BCAT1/ECA39. Overexpression of
BCAT1/ECA39 increases KIC levels, inhibiting cell growth
or promoting cell death. This model is in good agreement
with results from yeast, in which disruption of ECA39 accel-
erates growth [26] and addition of KIC inhibits growth (un-
published data).
BCAA are essential amino acids in mammals and are uti-
lized for protein synthesis. Degradation of BCAA and pro-
duction of BCKA occurs when energy sources are limited and
protein catabolism becomes the energy source of the organ-
ism. It is appealing to suggest that under such conditions keto
acids may serve as indicators for the metabolic state of the
cells. Thus, high levels of BCKA may indicate a catabolic
condition, producing an indirect suppressive e¡ect on cell pro-
liferation. Interestingly, a similar situation, in which amino
acid metabolites normally found in cells in low concentrations
induce cell death when overproduced, is found with another
Myc target: Ornithine decarboxylase (ODC) (Fig. 7). ODC
promotes the rate-limiting step in polyamine biosynthesis,
converting ornithine to putrescine. Overexpression of ODC
induces apoptosis in serum-starved cells [39], and ornithine
itself is su⁄cient to induce apoptosis in mouse melanoma cells
overproducing ODC [40], probably via accumulation of pu-
trescine [40,41].
From the accumulating information on Myc target genes it
is evident that Myc regulates the expression of genes involved
directly in control of the cell cycle (e.g. cdc25A, p53) but is not
restricted to cell cycle control. Myc regulates expression of
various metabolic enzymes as well, e.g. ODC [42], BCAT1/
ECA39 [7,9], carbamoyl-phosphate synthase (cad), [43], lac-
tate dehydrogenase (LDH-A) [44], and these enzymes are
also important mediators of Myc-induced processes [39,44].
Bcat1/Eca39 may be involved in yet another cellular proc-
ess. As mentioned, transamination of BCAA produces gluta-
mate in addition to BCKA. Glutamate is a widespread neuro-
transmitter, with cytotoxic e¡ects. Glutamate levels and
distribution in the brain are tightly regulated to allow produc-
tion of proteins and neurotransmitters, and at the same time,
prevent exposure of cells to the toxic e¡ects of glutamate
[45,46]. Transamination of BCAA, promoted by BCAT1/
ECA39, is believed to be the main mechanism for balancing
glutamate levels in the brain [45,46]. This would suggest that
Bcat1/Eca39 may play a role in brain development, Being a
Myc target gene, Bcat1/Eca39 may by related to Myc’s essen-
tial role in development.
Our interest in Myc target genes is based on the assumption
that understanding the mechanisms by which Myc transforms
cells will facilitate the development of drugs speci¢c for Myc-
induced tumors. The realization that Myc oncoproteins are
involved in apoptosis opens the ¢eld to try and shift the bal-
ance of cellular growth from proliferation to apoptosis in the
tumor. The isolation of target genes for Myc activity, which
are also involved in apoptosis, should assist us in the develop-
ment of reagents and strategies to control tumor growth.
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